Key clinical point: Adding low-dose rivaroxaban to low-dose aspirin following revascularization for symptomatic lower-extremity peripheral artery disease provided significantly greater clinical benefit in patients with comorbid coronary artery disease.
Major finding: The relative risk reduction in the primary composite endpoint was 22% with rivaroxaban plus aspirin, compared with aspirin alone in patients with peripheral artery disease and coronary artery disease, twice that seen in those with peripheral artery disease only.
Study details: This was a secondary subgroup analysis of the 3-year, international, randomized, double-blind, placebo-controlled 6,564-patient VOYAGER PAD trial.
Disclosures: The trial was sponsored by Bayer and Janssen. The presenter reported receiving research grant support from those two companies as well as Amgen.
Hiatt WR. ESC 2020.